Clinicopathological variables associated with PFS after BTKi initiation
| Pre-BTKi variable . | No. of patients . | Association with PFS after BTKi initiation . | |
|---|---|---|---|
| HR (95% CI) . | Log-rank P . | ||
| Age ≥65 y | 2.03 (0.23-17.7) | .515 | |
| Y | 20 | ||
| N | 3 | ||
| ≥4 prior lines of therapy | 0.38 (0.11-1.40) | .132 | |
| Y | 17 | ||
| N | 6 | ||
| Fludarabine refractory | 0.60 (0.18-2.04) | .416 | |
| Y | 15 | ||
| N | 8 | ||
| Bulky adenopathy (>5 cm) | NA | NA | |
| Y | 1 | ||
| N | 19 | ||
| NOTCH1 mutation | 0.67 (0.08-5.52) | .698 | |
| Y | 3 | ||
| N | 16 | ||
| IgHV unmutated | NA | NA | |
| Y | 13 | ||
| N | 1 | ||
| del(17p) and/or TP53 mutation | 2.24 (0.42-11.98) | .332 | |
| Y | 16 | ||
| N | 5 | ||
| CK | 0.69 (0.17-2.81) | .600 | |
| Y | 13 | ||
| N | 6 | ||
| BTKi post-RT* | 0.92 (0.25-3.43) | .898 | |
| Y | 5 | ||
| N | 18 | ||
| CR or uMRD to venetoclax | 0.15 (0.02-1.08) | .029 | |
| Y | 8 | ||
| N | 15 | ||
| ≥24 mo on venetoclax | 0.31 (0.09-1.03) | .044 | |
| Y | 14 | ||
| N | 9 | ||
| BCL2 G101V | 0.24 (0.05-1.16) | .054 | |
| Y | 8 | ||
| N | 11 | ||
| Pre-BTKi variable . | No. of patients . | Association with PFS after BTKi initiation . | |
|---|---|---|---|
| HR (95% CI) . | Log-rank P . | ||
| Age ≥65 y | 2.03 (0.23-17.7) | .515 | |
| Y | 20 | ||
| N | 3 | ||
| ≥4 prior lines of therapy | 0.38 (0.11-1.40) | .132 | |
| Y | 17 | ||
| N | 6 | ||
| Fludarabine refractory | 0.60 (0.18-2.04) | .416 | |
| Y | 15 | ||
| N | 8 | ||
| Bulky adenopathy (>5 cm) | NA | NA | |
| Y | 1 | ||
| N | 19 | ||
| NOTCH1 mutation | 0.67 (0.08-5.52) | .698 | |
| Y | 3 | ||
| N | 16 | ||
| IgHV unmutated | NA | NA | |
| Y | 13 | ||
| N | 1 | ||
| del(17p) and/or TP53 mutation | 2.24 (0.42-11.98) | .332 | |
| Y | 16 | ||
| N | 5 | ||
| CK | 0.69 (0.17-2.81) | .600 | |
| Y | 13 | ||
| N | 6 | ||
| BTKi post-RT* | 0.92 (0.25-3.43) | .898 | |
| Y | 5 | ||
| N | 18 | ||
| CR or uMRD to venetoclax | 0.15 (0.02-1.08) | .029 | |
| Y | 8 | ||
| N | 15 | ||
| ≥24 mo on venetoclax | 0.31 (0.09-1.03) | .044 | |
| Y | 14 | ||
| N | 9 | ||
| BCL2 G101V | 0.24 (0.05-1.16) | .054 | |
| Y | 8 | ||
| N | 11 | ||
Bold font indicates significance.
CI, confidence interval; CR, complete response; HR, hazard ratio; IgHV, immunoglobulin heavy chain variable region; NA, not applicable; RT, Richter transformation.
Patients receiving BTKi therapy for progressive CLL after treatment for RT on venetoclax with salvage chemotherapy ± autologous SCT.